Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEN-001 + avelumab in PD-L1+ gastric/GEJ adenocarcinoma
NCT05419362Phase 2Completed
- Sponsor
- Genome & Company
- Start
- Apr 2022
- Primary completion
- Aug 2024
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 2 trial of LR20011 in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Genome & Company. Started Apr 2022; status: completed.
02
Drugs
LR20011
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05419362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05419362.